FO
CLDX icon

FT Options’s Celldex Therapeutics CLDX Stock Holding History

FT Options’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,247
Closed -$9K – 204
2017
Q1 		$9K Sell
2,247
-1,000
-31% -$52.1K 0.01% 232
2016
Q4 		$27K Buy
3,247
+1,580
+95% +$89.9K 0.03% 164
2016
Q3 		$20K Buy
1,667
+1,187
+247% +$73.9K 0.02% 272
2016
Q2 		$1K Buy
+480
New +$30.5K ﹤0.01% 332

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FT Options's CLDX Position: Q3 2016 in Review

FT Options sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 87 shares — an estimated $5.42K sold.

FT Options first reported a position in CLDX in Q2 2016 and held it in 1 quarter. The position peaked at $6K in Q2 2016. 138 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • FT Options reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
  • FT Options sold 87 Celldex Therapeutics shares in Q3 2016, an estimated $5.42K.
  • FT Options first reported a position in Celldex Therapeutics in Q2 2016 and held it in 1 quarter.
  • FT Options's Celldex Therapeutics position peaked at $6K in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.